These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 22059912)
1. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Wang JN; Hu P; Zeng MS; Liu RB Chin J Cancer; 2011 Dec; 30(12):831-41. PubMed ID: 22059912 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Wang J; Hu P; Zeng M; Rabkin SD; Liu R Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767 [TBL] [Abstract][Full Text] [Related]
3. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus. Wang JN; Xu LH; Zeng WG; Hu P; Rabkin SD; Liu RR Asian Pac J Cancer Prev; 2015; 16(3):1241-5. PubMed ID: 25735362 [TBL] [Abstract][Full Text] [Related]
4. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Wang J; Xu L; Zeng W; Hu P; Zeng M; Rabkin SD; Liu R Cancer Cell Int; 2014; 14(1):83. PubMed ID: 25360068 [TBL] [Abstract][Full Text] [Related]
6. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Li J; Zeng W; Huang Y; Zhang Q; Hu P; Rabkin SD; Liu R Cancer Gene Ther; 2012 Oct; 19(10):707-14. PubMed ID: 22898897 [TBL] [Abstract][Full Text] [Related]
7. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer. Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624 [TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549 [TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231 [TBL] [Abstract][Full Text] [Related]
10. An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells. Liu RY; Zhou L; Zhang YL; Huang BJ; Ke ML; Chen JM; Li LX; Fu X; Wu JX; Huang W Biochem Biophys Res Commun; 2013 Dec; 442(3-4):171-6. PubMed ID: 24269822 [TBL] [Abstract][Full Text] [Related]
11. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413 [TBL] [Abstract][Full Text] [Related]
12. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Todo T Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691 [TBL] [Abstract][Full Text] [Related]
15. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516 [TBL] [Abstract][Full Text] [Related]
16. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Aghi M; Rabkin SD; Martuza RL Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749 [TBL] [Abstract][Full Text] [Related]
17. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells. Fan J; Jiang H; Cheng L; Liu R Oncol Rep; 2016 Mar; 35(3):1741-9. PubMed ID: 26718317 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583 [TBL] [Abstract][Full Text] [Related]
19. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340 [TBL] [Abstract][Full Text] [Related]